PARIS--(BUSINESS WIRE)--Regulatory News:
“Following the improved sales expectations and the savings resulting from discontinuation of all developments with tasquinimod in prostate cancer, we raise our sales and profitability guidance for 2015.”
Ipsen (Euronext: IPN; ADR: IPSEY) today reported its sales for the first quarter 2015.
Help employers find you! Check out all the jobs and post your resume.
“Following the improved sales expectations and the savings resulting from discontinuation of all developments with tasquinimod in prostate cancer, we raise our sales and profitability guidance for 2015.”
Ipsen (Euronext: IPN; ADR: IPSEY) today reported its sales for the first quarter 2015.
Help employers find you! Check out all the jobs and post your resume.
